T he use of antisense oligodeoxynucleotides (ODNs) as therapeutic agents for cancer, viral infection, and other diseases has recently gained great interest. Preclinical results, obtained by administering ODNs to specifically reduce the expression of several different genes responsible either for transformation or for maintenance of the malignant phenotype, 1 ± 3 demonstrated their potential role as novel therapeutic agents in cancer treatment with promising results. Because a major limitation to the widespread use of ODNs possessing natural phosphodiester linkages is their chemical sensitivity to nuclease degradation, ODN analogues displaying increased stability, unaltered specificity, and improved physicochemical and biological properties continue to be developed.
Phosphorothioates oligodeoxynucleotides ( [S ]ODNs) are the most widely explored analogues; 4 ± 6 their bioavailability is considerably greater than unmodified ODNs, even though they still exhibit a short half -life in blood, low accumulation in tissues, and poor intracellular penetration, mainly due to their ionic feature.
The use of lipid -based delivery systems represents an alternative to chemical modification for increasing the stability of ODNs in blood circulation and for improving their disease-site delivery and cell permeability. It has been recently reported that a liposomal formulation of raf [S ] ODNs significantly enhances the plasma and tissue levels of ODNs and improves its antitumoral effects in human laryngeal squamous carcinoma cells in vitro and in vivo. 7, 8 Liposomes are also able to improve the delivery of antisense targeting the human c -myb oncogene in different human tumor cells, 9 the multidrug resistance 1 (MDR1 ) gene in a multidrug resistant human B -lymphoma cell line 10 and the bcl -2 gene in follicular lymphoma cell lines. 11 Recently, Semple et al 12, 13 have developed a lipid -based formulation for ODNs that incorporates a number of features that are desirable for systemic delivery applications, including minimal surface charge, small particle size ($100 nm ), and long circulation times. The stabilized antisense lipid particles (SALP ) entrap ODNs within lipid bilayers at high ODN -to -lipid ratios, thereby protecting the ODNs in the biological milieu and enabling the delivery of intact ODNs into the tumor. We have previously demonstrated that c -myc antisense [ S ]ODNs inhibit tumor growth in some melanoma lines by specifically down -regulating c-myc protein. 14 In addition, we reported that c -myc ODNs potentiate the efficacy of cisplatin ( DDP ) in melanoma cells. 15 In particular, c -myc antisense ODNs treatment overcomes DDP resistance observed in a metastatic tumor line overexpressing c -myc protein. 16 Our aim was to evaluate if the encapsulation of c-myc antisense in SALP (SALP INX -6295 ) modifies the plasma pharmacokinetic and antitumor activity of the free c-myc antisense [ Clinical -grade DDP ( Cisplatino Teva ) was obtained from Teva Pharma ( Ind., Israel ) . DDP dilutions were freshly prepared before each experiment.
Preparation of SALP
INX -6295 and INX -6300 were encapsulated in lipid particles (SALP INX -6295 and SALP INX -6300 ) using an ethanol dialysis procedure and an ionizable aminolipid, as previously described. 12, 13 The SALP formulation consisted of distearoylphosphatidylcholine (DSPC ) / cho- ODNs were removed from the formulation by dialysis against HBS ( 10 mM Hepes, 145 mM NaCl, pH 7.5 ) , followed by DEAE -sepharose CL -6B anion exchange chromatography. The mean diameter and size distribution of SALP were determined using a NICOMP Model 370 submicron particle sizer, and was typically 110 30 nm.
Melanoma model
The NG human primary melanoma used in this study was obtained and transplanted as previously described.
14 Nude mice were injected in the hind leg muscle with a cell suspension of 2.5Â10 6 cells. A tumor mass was evident in all mice on day 4 after tumor implant. All experiments were carried out between the fifth and the eighth passage in nude mice. 24 , and 48 hours following administration, mice were euthanized and the tumors were excised and weighed. A saline solution was added to each tumor and a 10% tissue homogenate was prepared using a Polytron tissue homogenizer. The homogenized samples were mixed and aliquots (100 l) were transferred into 7 -mL glass scintillation vials ( duplicates ). Solvable 1 ( Packard Bioscience, Groningen, the Netherlands ) was added to each vial (0.5 mL /vial ) and the samples were heated at 658C until the tissue was fully digested. All samples were cooled for 1 hour at 48C and were subsequently decolorized for at least 1 hour following the addition of 50 l of 200 mM EDTA, 200 l of 30% hydrogen peroxide and 25 l of 10 N hydrochloric acid. Pico -Fluor 
Pharmacokinetic and tumor content analysis

Laser scanning confocal microscopy
For the laser scanning confocal microscopy (LSCM ) observations, NG melanoma tumor ±bearing mice were treated with 1 mg /mouse of free INX -6295 or SALP INX -6295 containing an FITC label. At 48 hours postadministration, mice were euthanized and the tumors were excised and immediately frozen. Three mice were used in each evaluation. Sections (50 m ) from the frozen tumors were prepared using a Reichert -Jung 2800 cryostat ( Reichert -Jung, Heidelberg, Germany ) and were subsequently mounted on glass microscope slides. The tissue sections were fixed with 3.7% paraformaldehyde for 10 min at room temperature, washed in phosphate buffer and mounted in 1:1 glycerol / phosphate buffer. Accumulation of FITC ± INX -6295 in tumor tissue was determined at excitation and emission wavelengths of 488 and 510 nm, respectively, using a LEICA TCS 4D laser scanning confocal microscope ( Leica Microsystems, Mannheim, Germany ). Identical
Cancer Gene Therapy, Vol 8, No 6, 2001 instrument acquisition parameters were used to analyze samples treated with either free INX -6295 or SALP INX -6295. Frozen NG melanoma tumors from untreated mice were used as a negative control. Each slide was optically sectioned ( 40± 60 optical sections) over the total thickness of the frozen section. The images are representative of several fields analyzed in each excised tumor. Threedimensional (3D ) reconstruction represents a 3D -image processing, in which all of the information received from the optical sections was imaged on the bidimensional screen. The acquisitions were recorded employing the pseudocolor intensity representation.
Western blot analysis
To evaluate the expression level of c-myc protein in solid tumors, 100 mg of mechanically disaggregated tumor was solubilized in lysis buffer. Each tumor lysate was obtained from a pool of three different tumors grown in mice treated with the different schedules. Briefly, proteins (30 g) were separated by 10% SDS -PAGE, transferred to nitrocellulose filters, and incubated with monoclonal antibodies specific for human p62 c -myc ( clone 9E10; Santa Cruz Biotechnology, Santa Cruz, CA ). After stripping, filters were incubated with anti -human -actin ( clone JLA 20; Oncogene Science, Manhasset, NY ) and anti --tubulin antibodies ( clone B -5 -1 -2; Sigma, Milan, Italy ). Reactivity was detected by enhanced chemiluminescence (Amersham International, Little Chalfont, Buckinghamshire, UK ) according to manufacturer's instructions. Levels of c -myc were quantified by scanning densitometry (Bio -Rad G700 ) of the autoradiography films and normalized to -actin andtubulin levels.
Histological analysis
The original tumor tissue fragments from mice untreated or treated with 1 mg / mouse of free INX -6295 or SALP INX -6295, preserved frozen in liquid nitrogen, were also used for conventional histological study. The tumors were fixed in 10% buffered formalin at + 48C overnight and embedded in paraffin. Five -micrometer sections were stained in hematoxylin and eosin. Three mice for each treatment group were analyzed. For each tumor, four different sections were evaluated.
In vivo treatments
Male CD -1 nude (nu /nu ) mice (6 ± 8 weeks old and 22 ± 24 g in body weight ) were purchased from Charles River Laboratories ( Calco, Italy ) . All procedures involving animals and their care were described previously and were in accordance with institutional guidelines and complied with national and international laws and policies. 15 In the drug combination experiments, three cycles of treatment at 7 -day intervals were administered according to the following schedules: free INX -6295 (schedule A ) , SALP INX -6295 (schedule B ) , free INX -6300 (schedule C ) , and SALP INX -6300 (schedule D ) were administered i.v. at 0.5 mg / mouse per day at days 7 ±14, 25 ±32, and 43± 50; DDP ( schedule E ) was injected i.p. at 3.3 mg /kg at days 4 ± 6, 22 ± 24, and 40 ±42; F= schedule A plus E; G =schedule B plus E; H = schedule C plus E; I= schedule D plus E. As controls, tumor-bearing mice were treated with Earle's balanced salts diluent or with empty lipid vesicles.
The tumor weight was calculated from caliper measurements according to the method of Geran et al. 17 Therapeutic efficacy of treatments was assessed by the following endpoints: ( a) percent tumor weight inhibition ( TWI% ) , calculated as [ 1À ( mean tumor weight of treated mice / mean tumor weight of controls ) ] Â100; ( b) tumor growth delay, evaluated as T À C, where T and C are the median times for treated and control tumors, respectively, to achieve equivalent size ( i.e., 1000 mg ); (c ) percent increase in life span ( ILS% ), calculated as [median survival time ( in days ) of treated mice/ median survival time (in days ) of control miceÀ 1]Â100.
Statistical analysis
The experimental results reported in Tables 2 and 3 were analyzed by the Mann -Whitney nonparametric test. Differences were considered significant at P values <.05 ( two sided ).
RESULTS
Plasma pharmacokinetics and tumor accumulation distribution of free and SALP INX -6295 in nude mice
The plasma pharmacokinetics of SALP INX -6295 and free INX -6295 were evaluated in athymic nude mice over a 24- ( Fig  1 ) . Moreover, encapsulation had a significant impact on the plasma pharmacokinetic parameters of the oligonucleotides. The area under the plasma concentration ± time curve ( AUC ) and peak plasma level (C max ) were increased $14 -and $2-fold, respectively, for SALP relative to free ODNs ( Table 1 ) ( Fig 3b ) a strong fluorescent signal, which was noticeably higher than that detected in free antisense ± treated NG melanoma cells (Fig  3a ) , was observed. Moreover, whereas SALP appeared to be accumulated within all cells of the tumor mass ( Fig 3, b and  d ) , free antisense ± treated samples displayed a discontinuous distribution of the fluorescent signal ( Fig 3, a and c) . When analyzed at higher magnification and subjected to 3D reconstruction (Fig 3, e and f ) , which represents all of the information from all of the optical sections analyzed and presents it in a unique image, it is evident that both SALP ODNs and free ODNs localized mainly within the nuclei of NG melanoma cells. Table 2 , no significant antitumor effects were observed in mice treated either with free or with SALP INX -6295 at the two lowest doses used (1 and 3 mg total dose /mouse) . A dose -dependent increase in the antitumor efficacy was observed in mice treated with free or SALP INX -6295, at the total dose of 6 and 8 mg /mouse. Moreover, SALP INX -6295 was more effective than free INX -6295 as evident when comparing the tumor weight inhibition at day 17 after the end of treatment (day 28 after tumor implant ) at doses of 6 and 8 mg / mouse as reported in Table 2 . Furthermore, it is worth noting that, at equivalent doses of the two formulations, different outcomes are observed: stable disease following treatment with SALP INX -6295 and tumor progression in animals treated with free INX -6295. In fact, while the treatment with SALP INX -6295 resulted in a stable inhibition of tumor mass (from day 28 to day 50 after tumor implant, TWI $50% for 6 mg / mouse and $60% for 8 mg /mouse) , the tumor weight inhibition elicited by free INX -6295 was decreased during the same observation period. In particular, at the highest dose of free antisense employed ( 8 mg /mouse) a significant difference between tumor weight evaluated at day 28 and at day 50 post implantation (p.i. ) was observed. Moreover, whereas animal survival was unaffected in mice that received free INX -6295, a significant increase in survival (P= .02 ) was observed for animals treated with SALP INX -6295. Tumor growth was unaffected following treatment with an equiv- 
Influence of liposome encapsulation of INX -6295 on c -myc protein expression
To examine whether the increased antitumor activity obtained following SALP INX -6295 treatment was correlated to differences in intratumoral c -myc protein levels, Western blot analysis was performed in tumors excised from mice treated at the highest dose level ( 1 mg / day per mouse for eight consecutive days ) . Analyses were performed on days 4 and 10 after the end of treatment. Densitometric analysis of c -myc protein expression normalized to the relative -actin andtubulin levels demonstrated that on day 4 after the end of treatment, an equivalent reduction of c-myc expression ( $80% ) was observed in tumors both from free and SALP-treated mice ( Fig 4A ) . On the contrary, on day 10 after the end of treatment, c-myc protein levels remained markedly decreased ($75% reduction ) in tumors from SALP-treated mice, whereas c -myc protein levels in tumors from animals treated with free INX -6295 had almost completely recovered ($25% reduction ). Taken together these data indicate that treatment with SALP INX -6295 provides a prolonged c -myc protein downregulation compared to the administration of free antisense. In contrast, c -myc protein levels detected in tumors from mice treated with c -myc scrambled [ S ]ODNs either free or encapsulated in SALP (free INX -6300 and SALP INX -6300, respectively ), were equivalent to levels of untreated tumors (Fig 4B ) . To ascertain whether the observed differences in c -myc protein expression levels were related to alterations in morphology of tumors, histological analysis was performed. Analysis performed at day 10 after the end of treatment (Fig 5 ) showed that all the tumors had a solid appearance and were highly invasive toward the muscle, without areas of necrosis; moreover, no substantial differences among the groups were observed.
Antitumor effect of free and SALP INX -6295 in combination with DDP
Because we have previously demonstrated that the c -myc antisense [S ] ODNs potentiate the antitumor efficacy of DDP, the administration of SALP INX -6295 was investigated in combination with DDP in NG melanoma ±bearing mice in an effort to further improve the therapeutic regimen. The schedule of administration was chosen on the basis of previous results obtained using free c -myc antisense [ S ]ODNs. 15 Table 3 shows the main endpoints evaluated after the different treatments. The results confirmed our previous data demonstrating that the combination of free cmyc antisense [S ]ODNs and DDP produced greater antitumoral activity in combination than that observed following administration of the two agents alone. 15 In fact, a significant inhibition of tumor weight ( 89%, P < .001 ) and tumor growth delay ( 32 days, P <.001 ) were observed after the combination treatment compared to DDP (67%, TWI; 14 days, T À C ) or free c-myc antisense [S ]ODNs (43%, TWI; 7 days, TÀ C ) administered separately. Moreover, the survival of mice treated with the combination was significantly increased (84% ) compared both to DDP ( 47%, P= .017) and free antisense ( 23%, P < .0001 ).
When NG tumor ± bearing mice were treated with SALP INX -6295 in combination with DDP, a similar tumor weight inhibition of 91% and tumor growth delay of 36 days, compared to the combination DDP /free INX -6295, were observed. The improved efficacy of the combination DDP / SALP INX-6295 was evident from the complete tumor regression observed in approximately 30% of mice at the end of the first cycle of treatment. This effect was maintained for at least 60 days following treatment, Western blot analysis performed on tumor lysates after combination treatments showed that the treatment with DDP did not change c-myc protein expression; the reduction of c -myc protein levels upon antisense treatment is similar to that observed after DDP /antisense combination ( data not shown) .
These data indicate that the combination of DDP and cmyc antisense encapsulated in SALP produces a significant increase in therapeutic efficacy compared to the combination of DDP and free c -myc antisense.
DISCUSSION
The incidence of human melanoma has recently reached a rate that equals that of the majority of all solid tumors. Despite the development of multimodal therapeutic approaches, the long -term survival of patients with melanoma has not improved over the last decade.
18 ± 20 New therapeutic strategies are continuously being explored for their clinical potential as alternative or adjuvant treatments. In several preclinical and clinical studies, treatment of melanoma with antisense ODNs designed to inhibit the expression of gene products important for melanoma cell growth, such as bcl -2 or c-myc, seems to be a new and promising approach.
14 ± 16,21 ± 23 However, although several key advances have been achieved in the area of medical chemistry, the majority of ongoing clinical trials involving antisense ODNs still use phosphorothioate [S ] ODNs. These molecules have several inherent problems, such as reduced binding affinities to mRNA targets, short plasma circulation half -life, and low clinical threshold dosing limits as a result of acute hemodynamic toxicities. In general, liposomes enhance the therapeutic index of conventional drugs through a combination of effects, including reduced drug toxicity, enhancement of plasma drug concentrations, and drug delivery to diseased tissue by extravasation of the carriers through hyperpermeable vasculature associated with tumor formation. 24 ± 28 The data presented in this study demonstrate that c -myc antisense encapsulated in SALP exhibited increased therapeutic efficacy over free c-myc antisense ODNs, in terms of both tumor mass reduction and delay of tumor regrowth. In this regard, stable tumor weight inhibition was observed for several weeks following the end of treatments in SALP INX -6295 ±treated animals, resulting in a significant increase in lifespan for these mice. In contrast, the survival of mice receiving free INX -6295 was unchanged even though, at the total dose of 8 mg /mouse, a tumor weight inhibition of 52% was observed. This TWI% was similar to that observed for SALP -treated mice at 6 mg /mouse. The increased survival observed at doses of 6 and 8 mg of SALP was likely due to the reduced rate at which the [ S ]ODNs were eliminated from the circulation. Previous studies using a liposome formulation of vincristine demonstrated a strong correlation between antitumor activity, circulation longevity, and increased vincristine tumor accumulation of liposomeencapsulated vincristine in a variety of murine tumor models. 29 ± 31 These findings were subsequently extended and confirmed in Phase I/II clinical trials, which have demonstrated the beneficial effects of liposome encapsulation in regard to improved pharmacokinetics and antitumor activity of liposomal vincristine in humans. 32, 33 The improved antitumor efficacy of SALP over free [ S] ODNs is consistent with the increased tumor accumulation and homogeneous distribution of [ S] ODNs within the NG tumors. The broad distribution of SALP/ FITC ± [ S] ODNs within the NG tumor mass was confirmed using LSCM analysis. Overall, the increased tumor accumulation of [ S] ODNs can be attributed to both the improved pharmacokinetic behavior and plasma AUC of the SALP [S ] ODNs, as well as the preferential accumulation of SALP in tumors and sites of inflammation, such as the intramuscular melanoma, which grows rapidly and is well vascularized. This hypothesis is supported by previous data, obtained using the same liposome formulation employed in this study, demonstrating that SALP exhibited enhanced accumulation in inflamed tissue in a murine model of delayed type hypersensitivity. 12, 34 Moreover, liposomes containing ICAM -1 antisense oligonucleotides improved the anti -inflammatory response of these agents. 35 The data presented in this study also demonstrate that the combination of SALP with DDP is more effective than the combination with free INX -6295. 15 Therefore, the sustained low level of c -myc expression may further enhance chemosensitization. Such an improvement in the efficacy of DDP could significantly alter the prognosis of melanoma and increase the potential for cure.
Finally, another important advantage of formulation of [ S ]ODNs in SALP is the potential for dose escalation in the clinical setting. Preclinical toxicology studies in cynomolgous monkeys have demonstrated that the general administration of [S ]ODNs can result in severe and acute hemodynamic and cardiovascular effects (hypotension, tachycardia ) , which are generally observed at peak [ S ]ODNs plasma concentrations >90 g /mL. This represents an approximate dose of 10 ±15 mg /kg, infused over 2 hours in monkeys. 36 In comparison, using the same infusion schedule, SALP INX -6295 has been administered in cynomolgous monkeys at doses up to 40 mg /kg of [ S ]ODNs without any changes in cardiovascular or hematological parameters (S. Semple et al, manuscript in preparation) . These findings may represent an important clinical advance toward increasing the MTD and patient compliance of antisense therapies.
Based on our findings demonstrating that the therapeutic efficacy of c -myc antisense [S ] ODNs is improved by encapsulation in SALP, the combination with DDP represents a potentially attractive strategy for therapeutic application in the clinical treatment of human melanoma.
